|
1
|
Bergsagel PL and Kuehl WM: Chromosome
translocations in multiple myeloma. Oncogene. 20:5611–5622. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chesi M and Bergsagel PL: Molecular
pathogenesis of multiple myeloma: Basic and clinical updates. Int J
Hematol. 97:313–323. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Morgan GJ, Walker BA and Davies FE: The
genetic architecture of multiple myeloma. Nat Rev Cancer.
12:335–348. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Egan JB, Shi CX, Tembe W, Christoforides
A, Kurdoglu A, Sinari S, Middha S, Asmann Y, Schmidt J, Braggio E,
et al: Whole-genome sequencing of multiple myeloma from diagnosis
to plasma cell leukemia reveals genomic initiating events,
evolution, and clonal tides. Blood. 120:1060–1066. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vincent Rajkumar S: Multiple myeloma: 2014
Update on diagnosis, risk-stratification and management. Am J
Hematol. 89:999–1009. 2014.PubMed/NCBI
|
|
6
|
Dillon LW, Burrow AA and Wang YH: DNA
instability at chromosomal fragile sites in cancer. Curr Genomics.
11:326–337. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Glover TW: Common fragile sites. Cancer
Lett. 232:4–12. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao G and Smith DI: Very large common
fragile site genes and their potential role in cancer development.
Cell Mol Life Sci. 71:4601–4615. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Debatisse M, Le Tallec B, Letessier A,
Dutrillaux B and Brison O: Common fragile sites: Mechanisms of
instability revisited. Trends Genet. 28:22–32. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sutherland GR and Richards RI: The
molecular basis of fragile sites in human chromosomes. Curr Opin
Genet Dev. 5:323–327. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Balsara BR, Pei J, De Rienzo A, Simon D,
Tosolini A, Lu YY, Shen FM, Fan X, Lin WY, Buetow KH, et al: Human
hepatocellular carcinoma is characterized by a highly consistent
pattern of genomic imbalances, including frequent loss of
16q23.1-24.1. Genes Chromosomes Cancer. 30:245–253. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paris PL, Witte JS, Kupelian PA, Levin H,
Klein EA, Catalona WJ and Casey G: Identification and fine mapping
of a region showing a high frequency of allelic imbalance on
chromosome 16q23.2 that corresponds to a prostate cancer
susceptibility locus. Cancer Res. 60:3645–3649. 2000.PubMed/NCBI
|
|
13
|
Hansen LL, Yilmaz M, Overgaard J, Andersen
J and Kruse TA: Allelic loss of 16q23.2-24.2 is an independent
marker of good prognosis in primary breast cancer. Cancer Res.
58:2166–2169. 1998.PubMed/NCBI
|
|
14
|
O'Keefe LV and Richards RI: Common
chromosomal fragile sites and cancer: Focus on FRA16D. Cancer Lett.
232:37–47. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ried K, Finnis M, Hobson L, Mangelsdorf M,
Dayan S, Nancarrow JK, Woollatt E, Kremmidiotis G, Gardner A,
Venter D, et al: Common chromosomal fragile site FRA16D sequence:
Identification of the FOR gene spanning FRA16D and homozygous
deletions and translocation breakpoints in cancer cells. Hum Mol
Genet. 9:1651–1663. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bednarek AK, Laflin KJ, Daniel RL, Liao Q,
Hawkins KA and Aldaz CM: WWOX, a novel WW domain-containing protein
mapping to human chromosome 16q23.3-24.1, a region frequently
affected in breast cancer. Cancer Res. 60:2140–2145.
2000.PubMed/NCBI
|
|
17
|
Paige AJ, Taylor KJ, Taylor C, Hillier SG,
Farrington S, Scott D, Porteous DJ, Smyth JF, Gabr H and Watson JE:
WWOX: A candidate tumor suppressor gene involved in multiple tumor
types. Proc Natl Acad Sci USA. 98:11417–11422. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ludes-Meyers JH, Bednarek AK, Popescu NC,
Bedford M and Aldaz CM: WWOX, the common chromosomal fragile site,
FRA16D, cancer gene. Cytogenet Genome Res. 100:101–110. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Paige AJ, Taylor KJ, Stewart A, Sgouros
JG, Gabra H, Sellar GC, Smyth JF, Porteous DJ and Watson JE: A
700-kb physical map of a region of 16q23.2 homozygously deleted in
multiple cancers and spanning the common fragile site FRA16D.
Cancer Res. 60:1690–1697. 2000.PubMed/NCBI
|
|
20
|
Alsop AE, Taylor K, Zhang J, Gabra H,
Paige AJ and Edwards PA: Homozygous deletions may be markers of
nearby heterozygous mutations: The complex deletion at FRA16D in
the HCT116 colon cancer cell line removes exons of WWOX. Genes
Chromosomes Cancer. 47:437–447. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Beroukhim R, Mermel CH, Porter D, Wei G,
Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J,
Urashima M, et al: The landscape of somatic copy-number alteration
across human cancers. Nature. 463:899–905. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bignell GR, Greenman CD, Davies H, Butler
AP, Edkins S, Andrews JM, Buck G, Chen L, Beare D, Latimer C, et
al: Signatures of mutation and selection in the cancer genome.
Nature. 463:893–898. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Krummel KA, Roberts LR, Kawakami M, Glover
TW and Smith DI: The characterization of the common fragile site
FRA16D and its involvement in multiple myeloma translocations.
Genomics. 69:37–46. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jenner MW, Leone PE, Walker BA, Ross FM,
Johnson DC, Gonzalez D, Chiecchio L, Dachs Cabanas E, Dagrada GP,
Nightingale M, et al: Gene mapping and expression analysis of 16q
loss of heterozygosity identifies WWOX and CYLD as being important
in determining clinical outcome in multiple myeloma. Blood.
110:3291–3300. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Agnelli L, Mosca L, Fabris S, Lionetti M,
Andronache A, Kwee I, Todoerti K, Verdelli D, Battaglia C, Bertoni
F, et al: A SNP microarray and FISH-based procedure to detect
allelic imbalances in multiple myeloma: An integrated genomics
approach reveals a wide gene dosage effect. Genes Chromosomes
Cancer. 48:603–614. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bednarek AK, Keck-Waggoner CL, Daniel RL,
Laflin KJ, Bergsagel PL, Kiguchi K, Brenner AJ and Aldaz CM: WWOX,
the FRA16D gene, behaves as a suppressor of tumor growth. Cancer
Res. 61:8068–8073. 2001.PubMed/NCBI
|
|
27
|
Driouch K, Prydz H, Monese R, Johansen H,
Lidereau R and Frengen E: Alternative transcripts of the candidate
tumor suppressor gene, WWOX, are expressed at high levels in human
breast tumors. Oncogene. 21:1832–1840. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gourley C, Paige AJ, Taylor KJ, Scott D,
Francis NJ, Rush R, Aldaz CM, Smyth JF and Gabra H: WWOX mRNA
expression profile in epithelial ovarian cancer supports the role
of WWOX variant 1 as a tumour suppressor, although the role of
variant 4 remains unclear. Int J Oncol. 26:1681–1689.
2005.PubMed/NCBI
|
|
29
|
Yendamuri S, Kuroki T, Trapasso F, Henry
AC, Dumon KR, Huebner K, Williams NN, Kaiser LR and Croce CM: WW
domain containing oxidoreductase gene expression is altered in
non-small cell lung cancer. Cancer Res. 63:878–881. 2003.PubMed/NCBI
|
|
30
|
Kuroki T, Trapasso F, Shiraishi T, Alder
H, Mimori K, Mori M and Croce CM: Genetic alterations of the tumor
suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer
Res. 62:2258–2260. 2002.PubMed/NCBI
|
|
31
|
Iliopoulos D, Guler G, Han SY, Johnston D,
Druck T, McCorkell KA, Palazzo J, McCue PA, Baffa R and Huebner K:
Fragile genes as biomarkers: Epigenetic control of WWOX and FHIT in
lung, breast and bladder cancer. Oncogene. 24:1625–1633. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Iliopoulos D, Fabbri M, Druck T, Qin HR,
Han SY and Huebner K: Inhibition of breast cancer cell growth in
vitro and in vivo: Effect of restoration of Wwox expression. Clin
Cancer Res. 13:268–274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cantor JP, Iliopoulos D, Rao AS, Druck T,
Semba S, Han SY, McCorkell KA, Lakshman TV, Collins JE, Wachsberger
P, et al: Epigenetic modulation of endogenous tumor suppressor
expression in lung cancer xenografts suppresses tumorigenicity. Int
J Cancer. 120:24–31. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ng MH, Chung YF, Lo KW, Wickham NW, Lee JC
and Huang DP: Frequent hypermethylation of p16 and p15 genes in
multiple myeloma. Blood. 89:2500–2506. 1997.PubMed/NCBI
|
|
35
|
Guillerm G, Gyan E, Wolowiec D, Facon T,
Avet-Loiseau H, Kuliczkowski K, Bauters F, Fenaux P and Quesnel B:
p16 (INK4a) and p15 (INK4b) gene methylations in plasma cells from
monoclonal gammopathy of undetermined significance. Blood.
98:244–246. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Stanganelli C, Arbelbide J, Fantl DB,
Corrado C and Slavutsky I: DNA methylation analysis of tumor
suppressor genes in monoclonal gammopathy of undetermined
significance. Ann Hematol. 89:191–199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Braggio E, Maiolino A, Gouveia ME,
Magalhães R, Souto Filho JT, Garnica M, Nucci M and Renault IZ:
Methylation status of nine tumor suppressor genes in multiple
myeloma. Int J Hematol. 91:87–96. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gonzalez M, Mateos MV, García-Sanz R,
Balanzategui A, López-Pérez R, Chillón MC, González D, Alaejos I
and San Miguel JF: De novo methylation of tumor suppressor gene
p16/INK4a is a frequent finding in multiple myeloma patients at
diagnosis. Leukemia. 14:183–187. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Heuck CJ, Mehta J, Bhagat T, Gundabolu K,
Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, et
al: Myeloma is characterized by stage-specific alterations in DNA
methylation that occur early during myelomagenesis. J Immunol.
190:2966–2975. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kaiser MF, Johnson DC, Wu P, Walker BA,
Brioli A, Mirabella F, Wardell CP, Melchor L, Davies FE and Morgan
GJ: Global methylation analysis identifies prognostically important
epigenetically inactivated tumor suppressor genes in multiple
myeloma. Blood. 122:219–226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tanaka H, Shimada Y, Harada H, Shinoda M,
Hatooka S, Imamura M and Ishizaki K: Methylation of the 5′ CpG
island of the FHIT gene is closely associated with transcriptional
inactivation in esophageal squamous cell carcinomas. Cancer Res.
58:3429–3434. 1998.PubMed/NCBI
|
|
42
|
Zöchbauer-Müller S, Fong KM, Maitra A, Lam
S, Geradts J, Ashfaq R, Virmani AK, Milchgrub S, Gazdar AF and
Minna JD: 5′ CpG island methylation of the FHIT gene is correlated
with loss of gene expression in lung and breast cancer. Cancer Res.
61:3581–3585. 2001.PubMed/NCBI
|
|
43
|
Ishii H, Vecchione A, Furukawa Y,
Sutheesophon K, Han SY, Druck T, Kuroki T, Trapasso F, Nishimura M,
Saito Y, et al: Expression of FRA16D/WWOX and FRA3B/FHIT genes in
hematopoietic malignancies. Mol Cancer Res. 1:940–947.
2003.PubMed/NCBI
|
|
44
|
Uehara E, Takeuchi S, Tasaka T, Matsuhashi
Y, Yang Y, Fujita M, Tamura T, Nagai M and Koeffler HP: Aberrant
methylation in promoter-associated CpG islands of multiple genes in
therapy-related leukemia. Int J Oncol. 23:693–696. 2003.PubMed/NCBI
|
|
45
|
Nakayama S, Semba S, Maeda N, Matsushita
M, Kuroda Y and Yokozaki H: Hypermethylation-mediated reduction of
WWOX expression in intraductal papillary mucinous neoplasms of the
pancreas. Br J Cancer. 100:1438–1443. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang X, Chao L, Jin G, Ma G, Zang Y and
Sun J: Association between CpG island methylation of the WWOX gene
and its expression in breast cancers. Tumour Biol. 30:8–142. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yan H and Sun J: Methylation status of
WWOX gene promoter CpG islands in epithelial ovarian cancer and its
clinical significance. Biomed Rep. 1:375–378. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
International Myeloma Working Group:
Criteria for the classification of monoclonal gammopathies,
multiple myeloma and related disorders: A report of the
International Myeloma Working Group. Br J Haematol. 121:749–757.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Greipp PR, San Miguel J, Durie BG, Crowley
JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H,
Kyle RA, et al: International staging system for multiple myeloma.
J Clin Oncol. 23:3412–3420. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Le Tallec B, Koundrioukoff S, Wilhelm T,
Letessier A, Brison O and Debatisse M: Updating the mechanisms of
common fragile site instability: How to reconcile the different
views? Cell Mol Life Sci. 71:4489–4494. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Abu-Odeh M, Salah Z, Herbel C, Hofmann TG
and Aqeilan RI: WWOX, the common fragile site FRA16D gene product,
regulates ATM activation and the DNA damage response. Proc Natl
Acad Sci USA. 111:E4716–E4725. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gourzones-Dmitriev C, Kassambara A, Sahota
S, Rème T, Moreaux J, Bourquard P, Hose D, Pasero P, Constantinou A
and Klein B: DNA repair pathways in human multiple myeloma: Role in
oncogenesis and potential targets for treatment. Cell Cycle.
12:2760–2773. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Aqeilan RI, Trapasso F, Hussain S,
Costinean S, Marshall D, Pekarsky Y, Hagan JP, Zanesi N, Kaou M,
Stein GS, et al: Targeted deletion of Wwox reveals a tumor
suppressor function. Proc Natl Acad Sci USA. 104:3949–3954. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ludes-Meyers JH, Kil H, Nuñez MI, Conti
CJ, Parker-Thornburg J, Bedford MT and Aldaz CM: WWOX hypomorphic
mice display a higher incidence of B-cell lymphomas and develop
testicular atrophy. Genes Chromosomes Cancer. 46:1129–1136. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ludes-Meyers JH, Kil H, Parker-Thornburg
J, Kusewitt DF, Bedford MT and Aldaz CM: Generation and
characterization of mice carrying a conditional allele of the Wwox
tumor suppressor gene. PloS One. 4:e77752009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Bouteille N, Driouch K, Hage PE, Sin S,
Formstecher E, Camonis J, Lidereau R and Lallemand F: Inhibition of
the Wnt/beta-catenin pathway by the WWOX tumor suppressor protein.
Oncogene. 28:2569–2580. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Fu J, Qu Z, Yan P, Ishikawa C, Aqeilan RI,
Rabson AB and Xiao G: The tumor suppressor gene WWOX links the
canonical and noncanonical NF-κB pathways in HTLV-I Tax-mediated
tumorigenesis. Blood. 117:1652–1661. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ekizoglu S, Bulut P, Karaman E, Kilic E
and Buyru N: Epigenetic and genetic alterations affect the WWOX
gene in head and neck squamous cell carcinoma. PloS One.
10:e01153532015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Huang C, Tian Y, Peng R, Zhang C, Wang D,
Han S, Jiao C, Wang X, Zhang H, Wang Y and Li X: Association of
downregulation of WWOX with poor prognosis in patients with
intrahepatic cholangiocarcinoma after curative resection. J
Gastroenterol Hepatol. 30:421–433. 2015. View Article : Google Scholar : PubMed/NCBI
|
